On Air Now

Current Show

Jerry Bader   8:30 AM - 11:00 AM

Text "JBSHOW" to 79489 and get updates from me. Email me at: jerrybadershow@mwcradio.com

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1360 AM Northeast, WI 97.5 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
57° Feels Like: 57°
Wind: NNW 7 mph Past 24 hrs - Precip: 0.02”
Current Radar for Zip

Today

Scattered Thunderstorms 67°

Tonight

Mostly Clear 36°

Tomorrow

Sunny 54°

Alerts

Breaking News

FOLLOW LIVE: Boston Marathon

Read More »

Impax, GSK end Parkinson's disease partnership

(Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.

Impax shares fell 2 percent to $17.32 in premarket trade after closing at $17.62 on Friday on the Nasdaq.

Under a deal, GlaxoSmithKline had the right to develop and market the drug, IPX066, outside the United States and Taiwan.

Rights to the drug, which is known as Rytary in the United States, will transfer back to Impax at the end of July 2013.

Impax did not disclose the financial impact of the deal termination, if any. It said it plans to find a partner or partners for markets outside the United States.

Rytary is an extended-release capsule being developed for the symptomatic treatment of adult patients with idiopathic Parkinson's disease.

(Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)

Comments